UCB has received a 5th nod for Bimzelx as hidradenitis suppurativa joins the fray of approved indications. We see an important role for Bimzelx in this emerging disease space with clear potential to become standard of care over time given its clear outperformance over Novartis' Cosentyx in the clinic. We reiterate our € 173 TP and Accumulate rating.
UCB shared first insights into the Phase 3 data on dapimap in SLE, which appear generally favourable with a 14.6% BICLA benefit after 48 weeks vs. SoC. The data also shows a steroid tapering effect and reduction in flares, while suggesting possible outperformance vs. current market leader Benlysta (GSK). Dapimap is co-developed with Biogen and will be continued in a second Ph3 study. We reiterate our € 173 TP and Accumulate rating.
We reiterate our BUY rating on UCB and increase our target price from €180 to €212. After almost a year on the ING Benelux Favourites List, we believe it is an opportune time to remove UCB as we view our upside as more risky than in the past as it is increasingly weighted towards UCB's development pipeline. Nonetheless, we remain confident in UCB's equity story, driven by INGF €6bn peak sales for Bimzelx, a continued strong performance of secondary growth engines Evenity and Rystiggo, as well as...
>Feedback analyst conference call - Alfen’s analyst call was hosted by CEO Marco Roeleveld, CCO Michele Lesh and CFO Onno Krab. Key topics were the following:Outlook per sector:- Smart Grid Solutions, substation production is to increase to c. 100 per week in Q4, but in H1 2025 will drop back to 70 per week because of customer constraints. Hopes H2 2025 to be able to up production further, but dependent on clients. Key clients are the grid operators as small...
>Feedback analyst conference call - Alfen’s analyst call was hosted by CEO Marco Roeleveld, CCO Michele Lesh and CFO Onno Krab. Key topics were the following:Outlook per sector:- Smart Grid Solutions, substation production is to increase to c. 100 per week in Q4, but in H1 2025 will drop back to 70 per week because of customer constraints. Hopes H2 2025 to be able to up production further, but dependent on clients. Key clients are the grid operators as small...
Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...
Alfen published Q3 2024 figures yesterday. Revenue came in at EUR106m (-18% QoQ vs. EUR129m in Q2 2024, -22% YoY vs. EUR136m in Q3 2023) pointing to EUR352m YTD (vs. cons. eyeing EUR489m for FY24). Q3 numbers were mostly impacted by modest revenue growth in Smart Grids (+1% YoY) and a sluggish pace
>Q3 better than consensus FY24 outlook slightly weaker = weaker Q4 - Revenues in-line, with strength in Smart Grids offsetting weakness in EV Charging. Revenues in 24Q3 were down 22% y-o-y to € 106.2m (1% below consensus of € 107.4m) with Smart Grid Solutions up 1% to € 50.3m (14% above consensus of € 44.3m), EV Charging Equipment down 6% to € 32.9m (14% below consensus of € 38.3m), and Energy Storage Systems down 55% to € 23.1m (consensus € 23.5m). Profitabil...
Adecco: 3Q24 miss; stabilising trends in 3Q24 and into 4Q24; accelerating cost savings. B&S Group: 3Q24 preview - liquor bottoming into 4Q24? Coca-Cola Europacific Partners: Almost the real thing. D'Ieteren: Belgian October car registrations down 5.5%, VW down 11%. Kinepolis: Oct US/Canada box office at 59% of pre Covid level, France recovery to 78%. Recticel: 3Q24 compares well with Kingspan. Renewi: 1H25 preview - battling cost inflation with self help. Syensqo: Slight beat on 3Q...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.